Chapman Steven Leonard sold $545K of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 1,698 shares of Natera, Inc. (NTRA) at $320.99 ($0.55M total) on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Sep 4, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 1:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosed sale is modest in size and likely to have limited price impact, but may be noted by short‑term traders.

02

Market read

Routine insider sale with modest size; low trading relevance.

03

What to watch

CEO retains a large stake (98,199 shares), indicating continued confidence.

Relevance 4/10Novelty 3/10Timing: filing date 2026‑09‑01

Background

Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

CEO Steven Leonard sold 1,698 shares for $545K via a 10b5‑1 plan, reducing his stake to 98,199 shares.

Expected impact

Potential short‑term pressure on NTRA, likely limited to a few basis points.

Evidence & confidence

Sale is under $1M and typical for a 10b5‑1 plan; market may view it as neutral to slightly negative.

Market effects

Minimal impact on the biotech sector; insider sales are common and not sector‑wide.

No regional effect beyond NTRA shareholders.

Limited to investors tracking insider activity.

Counterpoint

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • Steven Leonard Chapman

    CEO and President of Natera, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.